CPCI CHANGES NAME TO IBEX TECHNOLOGIES INC. AND SYMBOLS TO IBT.A AND IBT.B.MONTREAL, QUEBEC--(BUSINESS WIRE)--AUGUST 29, 1995--IBEX TECHNOLOGIES INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. .(ME, TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). : IBT (1) (Instructor Based Training) Training courses conducted by human teachers. (2) (Internet Based Training) Training courses provided via the Internet. .A IBT.B) Continental Pharma Cryosan Inc., "CPCI See CompactPCI. ", announces that it has officially changed its name to IBEX ibex (ī`bĕks), wild goat, genus Capra, found in rugged country on mountain ranges from central Asia to the Himalayas, S Europe, and NE Africa. Technologies Inc. The Company's shares, which traded under the ticker symbols CPM.A and CPM.B, will begin trading today under the new symbols IBT.A, and IBT.B. The change of name reflects the refocusing of CPCI exclusively on its biotechnology business, IBEX Technologies, following the sale of CPCI's home healthcare operations in May of this year. Senior Management Changes In line with the transformation of the Company, a number of senior management changes have been made: - Mr. Paul Baehr, currently the Vice-Chairman of IBEX Technologies Inc., has been named Chairman. Mr. Baehr joined IBEX in 1994 after a distinguished pharmaceutical career in the US with Swiss multinational Ciba-Geigy and latterly, as Executive Vice-President of the Kodak pharmaceutical subsidiary, Sterling Winthrop Inc. - Dr. Robert Heft, currently the President of IBEX Technologies, has become President and Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Dr. Heft received his Ph.D from M.I.T. and became President of IBEX when the Company was formed in 1988. - Thomas O. Hecht will be named Chairman Emeritus as he steps down from his position as Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CPCI and Chairman of IBEX Technologies. Mr. Baehr stated "We are pleased to have the continued benefit of Tom Hecht's wise counsel as we move forward. Tom, as CEO of CPCI, had the foresight to invest in IBEX six years ago and has played a significant role in nurturing IBEX to its current favourable position". Board of Directors In addition to Paul Baehr and Dr. Robert Heft joining the Board of Directors, the Board welcomes its other new member, Bernard Coupal of Societe Innovatech du Grand Montreal. These three new directors replace Joseph Rotman, H. Thomas Beck and Peter Snucins who have resigned from the Board to make way for the new management. Continuing on the board will be Thomas O. Hecht, Emmett Pearson, John Bennett and Sidney Horn. Profile IBEX Technologies Inc. is a Canadian biopharmaceutical company developing enzyme-based therapeutics. The Company's first enzyme-based therapeutic product, Neutralase(TM), recently completed Phase IA clinical trials for heparin neutralization neutralization, chemical reaction, according to the Arrhenius theory of acids and bases, in which a water solution of acid is mixed with a water solution of base to form a salt and water; this reaction is complete only if the resulting solution has neither acidic nor after bypass surgery. A second therapeutic agent, based on technology licensed from McGill University, will soon enter formal development for the treatment of phenylketonuria phenylketonuria (fĕn'əlkēt'ən  r`ēə) (PKU), inherited metabolic disorder caused by the absence of a specific enzyme (phenylalanine hydroxylase). . IBEX has developed and commercialized three diagnostic products based on its core technology, and is marketing these products through corporate partners. CONTACT: Paul Baehr Chairman & Chief Executive Officer Dr. Robert Heft President & Chief Operating Officer 514/344-4004 REPEATS: New York 212-575-8822 or 800-221-2462; Boston 617-330-5311 or 80 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion